2007
DOI: 10.1016/j.str.2007.10.014
|View full text |Cite
|
Sign up to set email alerts
|

Phosphorylation-Induced Conformational Switching of CPI-17 Produces a Potent Myosin Phosphatase Inhibitor

Abstract: Phosphorylation of endogenous inhibitor proteins for type-1 Ser/Thr phosphatase (PP1) provides a mechanism for reciprocal coordination of kinase and phosphatase activities. A myosin phosphatase inhibitor protein CPI-17 is phosphorylated at Thr38 through G-protein-mediated signals, resulting in a >1000-fold increase in inhibitory potency. We show here the solution NMR structure of phospho-T38-CPI-17 with rmsd of 0.36 +/- 0.06 A for the backbone secondary structure, which reveals how phosphorylation triggers a c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
47
0
1

Year Published

2008
2008
2016
2016

Publication Types

Select...
8
1

Relationship

4
5

Authors

Journals

citations
Cited by 46 publications
(49 citation statements)
references
References 61 publications
1
47
0
1
Order By: Relevance
“…As indicated in a recent paper by Eto et al (17), CPI-17 phosphorylation induced conformational changes in CPI-17, making it a potent inhibitor of MLCP. Thus, phosphorylated CPI-17 caused increased inhibition of MLCP activity (27).…”
Section: Discussionmentioning
confidence: 88%
“…As indicated in a recent paper by Eto et al (17), CPI-17 phosphorylation induced conformational changes in CPI-17, making it a potent inhibitor of MLCP. Thus, phosphorylated CPI-17 caused increased inhibition of MLCP activity (27).…”
Section: Discussionmentioning
confidence: 88%
“…Therefore, the autoinhibitory domain of MYPT1 likely recognizes the active site modulated by the allosteric regulation with the N-terminal domain of MYPT1. Interestingly, the N-terminal 19 residues of MYPT1, located near the PP1 active site, are directly associated with phosphorylated CPI-17 (59). Therefore, it is also possible that the autoinhibitory domain recognizes the MYPT1 N-terminal segment as a marker of the active site.…”
Section: Discussionmentioning
confidence: 99%
“…58,59 Computer modeling predicts direct binding between MYPT1 and phospho-CPI-17, suggesting that MYPT1 may dock CPI-17 to the MLCP holoenzyme, accounting for the specific inhibition of MLCP by CPI-17. 60 Furthermore, when bound to MYPT1, the PPP1Cd catalytic subunit of MLCP is unable to hydrolyze phospho-Thr38 of CPI-17, so phospho-CPI-17 is able to bind at the active site of PPP1Cδ and suppress its activity.…”
Section: Inhibition Of Myosin Light Chain Phosphatase Activity By Cpimentioning
confidence: 99%